Paper25754718
Hypersensitivity to biological agents-updated diagnosis, management, and treatment.
Galvão VR and 1 other. J Allergy Clin Immunol Pract, 2015. Cited by 92 papers, by iCite.
Cite this record
ConductScience Library. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. Papers, record 25754718. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25754718
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biological Factors | Major topic |
| Drug Hypersensitivity | Major topic |
| Desensitization, Immunologic | |
| Humans |
Source PubMed
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 92 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42755765 | Clinical phenotypes, endotypes, and biomarker profiles of immediate rituximab hypersensitivity reactions: a prospective pharmacovigilance study. | Front Allergy | 2026 | https://conductscience.org/library/papers/42755765 | PubMed |
| 42677058 | Anifrolumab for rituximab-induced SCLE and cryoglobulinemic vasculitis in primary Sjögren's disease: a case report. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42677058 | PubMed |
| 42583107 | Safety signals for drug-related respiratory depression: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS). | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42583107 | PubMed |
| 41937341 | Immediate and delayed hypersensitivity to biologicals in children-A practical approach: An EAACI task force report. | Pediatr Allergy Immunol | 2026 | https://conductscience.org/library/papers/41937341 | PubMed |
| 41634892 | Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study. | J Pharm Health Care Sci | 2026 | https://conductscience.org/library/papers/41634892 | PubMed |
| 40051429 | Allergy to ustekinumab: Validating skin tests for diagnostic and therapeutic decision-making. | Asia Pac Allergy | 2025 | https://conductscience.org/library/papers/40051429 | PubMed |
| 40051428 | Effective desensitization in an IgE-mediated hypersensitivity reaction to tocilizumab in neuromyelitis optica. | Asia Pac Allergy | 2025 | https://conductscience.org/library/papers/40051428 | PubMed |
| 39961769 | The impact of repeated drug desensitisation on quality of life in drug hypersensitivity. | Clin Transl Allergy | 2025 | https://conductscience.org/library/papers/39961769 | PubMed |
| 39816201 | Multiple Successful Desensitizations to Brentuximab Vedotin in the Setting of Relapsed Peripheral T-Cell Lymphoma: Case Report. | Can J Hosp Pharm | 2025 | https://conductscience.org/library/papers/39816201 | PubMed |
| 39630768 | Conclusions of clinical trials assessing monoclonal antibodies and sponsored by pharmaceutical industry: a meta-research study. | Rev Assoc Med Bras (1992) | 2024 | https://conductscience.org/library/papers/39630768 | PubMed |
| 39434186 | Retrospective analysis of rapid drug desensitization with biologic agents: A single center experience. | Clin Transl Allergy | 2024 | https://conductscience.org/library/papers/39434186 | PubMed |
| 39001293 | Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients. | Diagnostics (Basel) | 2024 | https://conductscience.org/library/papers/39001293 | PubMed |
| 37404435 | A Case of VEXAS: Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic Syndrome With Co-existing DNA (Cytosine-5)-Methyltransferase 3A Mutation Complicated by Localized Skin Reaction to Tocilizumab and Azacitidine. | Cureus | 2023 | https://conductscience.org/library/papers/37404435 | PubMed |
| 36911456 | Successful Rapid Desensitization of a Pediatric Multiple Sclerosis Patient with Anaphylaxis to Ocrelizumab. | Ann Indian Acad Neurol | 2022 | https://conductscience.org/library/papers/36911456 | PubMed |
| 36160076 | Successful Rapid Drug Desensitization with A Modified Protocol To Alemtuzumab in A Multiple Sclerosis Patient with Severe Immediate-Type Hypersensitivity Reaction. | Noro Psikiyatr Ars | 2022 | https://conductscience.org/library/papers/36160076 | PubMed |
| 35286851 | Mechanistic contributions of Kupffer cells and liver sinusoidal endothelial cells in nanoparticle-induced antigen-specific immune tolerance. | Biomaterials | 2022 | https://conductscience.org/library/papers/35286851 | PubMed |
| 34939919 | Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases. | Dtsch Arztebl Int | 2022 | https://conductscience.org/library/papers/34939919 | PubMed |
| 34463914 | Non-IgE-Mediated Drug Hypersensitivity Reactions. | Curr Allergy Asthma Rep | 2021 | https://conductscience.org/library/papers/34463914 | PubMed |
| 34319562 | Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. | Clin Rev Allergy Immunol | 2022 | https://conductscience.org/library/papers/34319562 | PubMed |
| 34186142 | Optimizing drug inhibition of IgE-mediated anaphylaxis in mice. | J Allergy Clin Immunol | 2022 | https://conductscience.org/library/papers/34186142 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25754718
GET https://conductscience.org/api/papers/v1/25754718/cited_by?page=2